Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Centre, Placebo-controlled Study to Evaluate the Combined Effect of Hyperglycaemia and a QTc-prolonging Medication on Cardiac Repolarisation in Male and Female Patients With Insulin Resistant Type 2 Diabetes Mellitus (T2DM)

NCT07014735 is registered in ClinicalTrials.gov with Richmond Pharmacology Limited as lead sponsor.

NCT NCT07014735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07014735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Centre, Placebo-controlled Study to Evaluate the Combined Effect of Hyperglycaemia and a QTc-prolonging Medication on Cardiac Repolarisation in Male and Female Patients With Insulin Resistant Type 2 Diabetes Mellitus (T2DM)
Lead sponsor
Richmond Pharmacology Limited
Phase
Not applicable
Overall status
Terminated
Start date
April 13, 2023
Completion date
May 31, 2026
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes type 2, hyperglycaemia (diabetic), qt interval, variation in, torsades de pointes